MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

News of the day

Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia

MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP. This study follows the recent presentation of positive Phase 2 data in infants, which showed that, in the majority of patients, six months of treatment with... more

GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus

Monday 2nd November 2009, London UK & Philadelphia US --GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Benlysta(TM) (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured... more

AXIS-SHIELD RECEIVES FDA CLEARANCE FOR THE ANTI-CCP RHEUMATOID ARTHRITIS TEST ON ABBOTT'S ARCHITECT ANALYSER

Dundee, Scotland, 16 October, 2009: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in vitro diagnostics (IVD) company, today announces that it has received marketing clearance from the US Food and Drug Administration (FDA) for an assay for anti-CCP, used in the diagnosis of rheumatoid arthritis (RA), to run on Abbott's Architect more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients
SAN DIEGO, CA, October 08, 2009 -- Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP(TM) in wet-AMD...

Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
BERKELEY, Calif. - October 8, 2009 -- Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating...

IDEA updates on Diractin
Munich, Germany - October 7, 2009. IDEA AG today announced the results and implications of two phase III clinical studies comparing the targeted analgesic Diractin

Zelos Therapeutics Initiates Clinical Study of First US Injectable Equivalent to Forteo
West Conshohocken, PA - (October 7, 2009) - Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is...

Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
Sep. 22, 2009 -- Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel(TM)). Produced using the Company's proprietary ProCellEx(TM)...

Integra NeuroSciences Features New MAYFIELD(R) Infinity XR2 Radiolucent Cranial Stabilization System At World Congress of Neurological Surgery
PLAINSBORO, N.J., August 31, 2009 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) is featuring the MAYFIELD(R) Infinity XR2 Radiolucent Cranial Stabilization System at the XIV World Congress of Neurological...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
EthyPharm
ShareVault
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us